Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study
This study underscores the importance of cardiovascular monitoring in CLL patients undergoing ibrutinib therapy, particularly those with pre-existing cardiovascular conditions. These findings highlight the need for individualized treatment planning and close follow-up to mitigate the risk of cardiotoxicity and optimize patient outcomes.
Authors
- Darko Antić (ORCID: https://orcid.org/0000-0002-2608-1342)
- Tamara Bibic
- Vladimir Otašević (ORCID: https://orcid.org/0000-0002-8690-1357)
- Kristina Tomić (ORCID: https://orcid.org/0009-0001-1573-570X)
- Vojin Vuković (ORCID: https://orcid.org/0000-0003-1069-8214)
- Nataša Milić (ORCID: https://orcid.org/0000-0001-7074-1187)
- Ksenija Marković
- Sofija Kozarac (ORCID: https://orcid.org/0009-0006-5949-3948)
- Jovan Kulić
- Jelena Vladičić Mašić (ORCID: https://orcid.org/0009-0000-4960-2959)
- Jelena Ivanovic
Institutions
- University of East Sarajevo (BA)
- University of Belgrade (RS)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fonc.2025.1624761
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63